Sunshine Biopharma (SBFM) EBITDA Margin (2015 - 2026)
Sunshine Biopharma's (SBFM) quarterly EBITDA Margin came in at 17.41% in Q2 2026, up 365.0% on a YoY basis from 3.74% in Q2 2025, and down 0.91% quarter-over-quarter from 17.25% in Q1 2026.
Powered by 
Analysis
Sunshine Biopharma (SBFM) EBITDA Margin (2015 - 2026) Analysis & Trends
Sunshine Biopharma (SBFM) has reported EBITDA Margin for 10 consecutive years, with 17.41% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBITDA Margin rose 365.0% year-over-year to 17.41%; the trailing twelve-month figure through Jun 2026 stood at 16.54% (up 81.0% YoY), and the FY2025 full-year result was 16.67%, down 42.0% from the prior year.
- EBITDA Margin slipped to 17.41% in Q2 2026 per SBFM's latest filing, from 17.25% in the prior quarter.
- Across five years, EBITDA Margin topped out at 10.52% in Q3 2025 and bottomed at 1292.99% in Q3 2022.
- Historically, EBITDA Margin has averaged 199.48% across 5 years, with a median of 17.51% in 2023.
- The widest YoY moves for EBITDA Margin: up 218161 bps in 2022, down 31420 bps in 2022.
- Over 5 years, EBITDA Margin stood at 592.64% in 2022, then surged by 97 bps to 15.41% in 2023, then slumped by 39 bps to 21.36% in 2024, then dropped by 1 bps to 21.53% in 2025, then climbed by 19 bps to 17.41% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 17.41%, 17.25%, and 21.53% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | -5.58% |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 0.17% |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 4.69% |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 16.30% |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 25.95% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | -134.08% |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 15.21% |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 21.60% |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | 9.72% |
| 10 | Sunshine Biopharma | 1.55 Mn | -12.20 Mn | 2.43 Mn | -17.41% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -17.41% |
| Mar 31, 2026 | -17.25% |
| Dec 31, 2025 | -21.53% |
| Sep 30, 2025 | -10.52% |
| Jun 30, 2025 | -21.06% |
| Mar 31, 2025 | -13.83% |
| Dec 31, 2024 | -21.36% |
| Sep 30, 2024 | -12.35% |
| Jun 30, 2024 | -13.09% |
| Mar 31, 2024 | -17.34% |
| Dec 31, 2023 | -15.41% |
| Sep 30, 2023 | -12.46% |
| Jun 30, 2023 | -17.61% |
| Mar 31, 2023 | -37.37% |
| Dec 31, 2022 | -592.64% |
| Sep 30, 2022 | -1,292.99% |
| Jun 30, 2022 | -461.40% |
| Mar 31, 2022 | -994.95% |
| Dec 31, 2021 | -324.78% |
| Sep 30, 2021 | -978.79% |